VIVANI MEDICAL, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.81 USD | +5.23% |
|
+1.69% | +77.45% |
| Mar. 26 | Vivani Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Mar. 06 | Vivani Medical, Inc. Appoints Daniel Bradbury to Its Board of Directors | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 99.51M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.62
x | P/E ratio 2025 * |
-3.23
x | Employees | 44 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.23% | ||
| 1 week | +1.69% | ||
| Current month | +11.73% | ||
| 1 month | -12.14% | ||
| 3 months | +77.45% | ||
| 6 months | +90.13% | ||
| Current year | +77.45% |
1 week
1.68
1.82
1 month
1.612.08
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | - | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.81 | +5.23% | 96,955 |
| 24-05-09 | 1.72 | +1.18% | 48,393 |
| 24-05-08 | 1.7 | -1.73% | 38,924 |
| 24-05-07 | 1.73 | -3.35% | 71,729 |
| 24-05-06 | 1.79 | +0.56% | 99,726 |
End-of-day quote Nasdaq, May 09, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.81
USD
Average target price
8
USD
Spread / Average Target
+341.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.45% | 99.51M | |
| +10.39% | 126B | |
| -6.86% | 10.96B | |
| +2.52% | 8.97B | |
| +38.96% | 5.56B | |
| -17.50% | 4.99B | |
| +8.36% | 3.44B | |
| -8.84% | 2.8B | |
| -7.52% | 2.18B | |
| -3.00% | 2.16B |
- Stock Market
- Equities
- VANI Stock